Using blood samples to find important genetic changes in lymphoma patients in Texas
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
This study is testing if blood samples can help find important genetic changes in patients with diffuse large B-cell lymphoma in Texas to see how well they respond to treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 517 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Locations | 2 sites (Houston, Texas and 1 other locations) |
| Trial ID | NCT05676450 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the feasibility and clinical utility of collecting cell-free DNA (cfDNA) from patients with diffuse large B-cell lymphoma (DLBCL) before and after treatment. By analyzing cfDNA, the study seeks to identify actionable genetic alterations and assess minimal residual disease across various community centers in Texas. The primary objective is to determine how effectively cfDNA can provide prognostic information and track molecular responses during and after therapy. Additionally, the study will explore the relationship between cfDNA levels and patient outcomes, including event-free survival (EFS) and overall survival (OS).
Who should consider this trial
Good fit: Ideal candidates include adult patients aged 18 and older with histologically confirmed diffuse large B-cell lymphoma who require therapy.
Not a fit: Patients who are pregnant or cognitively impaired will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the ability to monitor treatment responses and tailor therapies for lymphoma patients based on genetic insights.
How similar studies have performed: Other studies have shown promise in using cfDNA for monitoring cancer treatment, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male/female patients who are at least 18 years of age on the day of informed consent signing. 2. Patients must have a histologically documented diffuse large B-cell lymphoma requiring therapy. 3. Provision of written informed consent for the study. 4. Pregnant women not included 5. Cognitively impaired adults are not included. Exclusion Criteria: None
Where this trial is running
Houston, Texas and 1 other locations
- MD Anderson Cancer Center — Houston, Texas, United States (Recruiting)
- Cancer Therapy and Research Center at The UT Health Science Center at San Antonio — San Antonio, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Chijioke Nze, MD — M.D. Anderson Cancer Center
- Study coordinator: Chijioke Nze, MD
- Email: CCNze@mdanderson.org
- Phone: 832-729-1752
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.